Growth Hormone Treatment in Children With Hypophosphatemic Rickets

Proposition Pour un Traitement Par Hormone de Croissance Des Enfants Atteints de Rachitisme Hypophosphatemique Familial

Status

Completed

Phases

Phase 1Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02720770

Acronym

GH-XLH

Enrollment

Registered

2016-03-28

Start date

2006-01-31

Completion date

2011-01-31

Last updated

2016-03-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

X Linked Hypophosphatemic Rickets

Keywords

growth hormone

Brief summary

This study evaluates the effect on height of a two year treatment with growth hormone in 19 children with X linked hypophosphatemic rickets.

Interventions

DRUGnorditropine simplex

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

3 Years to 14 Years

Healthy volunteers

Inclusion criteria

* clinical, biochemical and genetic diagnosis of XLH * height SDS \< 2 * at least two years of treatment with oral phosphate and calcitriol

Exclusion criteria

* uncontrolled rickets (ALP\>600 IU) * growth hormone deficiency * hyperparathyroidism, nephrocalcinosis, renal insufficiency * associated disease * previous treatment with growth hormone

Design outcomes

Primary

Measure	Time frame
change from baseline in height SDS (standard deviation score)	at year one and year two from baseline

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 9, 2026